Cartesian Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed Apr 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 30, 2026
RNAC$6.89-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of March and December 31,
Consolidated Balance Sheets
(Amounts in thousands, except share data and par value)
| March 31, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $118,641 | $125,139 |
| Accounts receivable | 261 | 1,115 |
| Prepaid expenses and other current assets | 3,137 | 3,022 |
| Total current assets | 122,039 | 129,276 |
| Property and equipment, net | 11,637 | 12,185 |
| Right-of-use assets, net | 5,366 | 5,601 |
| In-process research and development asset | 93,900 | 93,900 |
| Goodwill | 48,163 | 48,163 |
| Long-term restricted cash | 1,735 | 1,735 |
| Long-term prepaid expenses and other assets | 5,551 | 5,551 |
| Total assets | $288,391 | $296,411 |
| Liabilities and stockholders’ deficit | ||
| Current liabilities: | ||
| Accounts payable | $1,598 | $1,288 |
| Accrued expenses and other current liabilities | 10,161 | 9,498 |
| Lease liabilities | 4,186 | 4,151 |
| Total current liabilities | 15,945 | 14,937 |
| Lease liabilities, net of current portion | 7,669 | 8,525 |
| Warrant liability | 47 | 141 |
| Contingent value right liability | 405,900 | 392,100 |
| Deferred tax liabilities, net | 6,948 | 6,948 |
| Total liabilities | 436,509 | 422,651 |
| Commitments and contingencies (Note 14) | ||
| Stockholders’ deficit: | ||
| Series A Preferred Stock, $0.0001 par value; 134,904.563 shares authorized as of March 31, 2026 and December 31, 2025; 120,790.402 shares issued and outstanding as of March 31, 2026 and December 31, 2025 | — | — |
| Series B Preferred Stock, $0.0001 par value; 437,927 shares authorized as of March 31, 2026 and December 31, 2025; 437,927 shares issued and outstanding as of March 31, 2026 and December 31, 2025 | — | — |
| Preferred stock, $0.0001 par value; 9,427,168.437 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued and outstanding as of March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value; 350,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 28,544,728 and 26,011,106 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 3 | 3 |
| Additional paid-in capital | 718,017 | 700,706 |
| Accumulated deficit | (861,555) | (822,373) |
| Accumulated other comprehensive loss | (4,583) | (4,576) |
| Total stockholders’ deficit | (148,118) | (126,240) |
| Total liabilities and stockholders’ deficit | $288,391 | $296,411 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.